LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today an…
Author: Business Wire
NovaBay Pharmaceuticals to Hold Third Quarter 2019 Conference Call on November 7, 2019
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, announces that it will report third quarter 2019 financial resu…
Resumen: La EMA y la FDA aceptan solicitudes de comercialización para satralizumab de Chugai en el trastorno del espectro de la neuromielitis óptica (NMOSD)
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) ha anunciado que la Agencia Europea de Medicamentos (EMA) ha aceptado la solicitud de autorización de comercialización para satralizumab (código de desarrollo: SA237), un receptor an…
Samenvatting: EMA en FDA accepteren marketingtoepassingen voor Chugai’s Satralizumab bij Neuromyelitis Optica Spectrum Disorder (NMOSD)
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) kondigde aan dat het Europees Geneesmiddelenbureau (EMA) de aanvraag voor een vergunning voor het in de handel brengen van satralizumab (ontwikkelingscode: SA237), een anti-interleuk…
EMA和FDA受理中外製藥用於泛視神經脊髓炎(NMOSD)的satralizumab的行銷申請
東京–(BUSINESS WIRE)–(美國商業資訊)–中外製藥株式會社(Chugai Pharmaceutical Co., Ltd., TOKYO: 4519)宣布，歐洲藥品管理局(EMA)已受理satralizumab（開發代碼：SA237）的行銷授權申請，該藥是一種抗白介素6 (IL-6)受體人化回收型抗體，用於治療成人和青少年泛視神經脊髓炎(NMOSD)患者。EMA已授予satralizumab加速評估(Accelerated Assessment)狀態。美國食品藥品管理局(FDA)…
EMA und FDA nehmen Zulassungsanträge für Satralizumab gegen Neuromyelitis-optica-Spektrum-Erkrankungen (NMOSD) von Chugai entgegen
TOKIO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519), hat bekannt gegeben, dass die Europäische Arzneimittel-Agentur (EMA) den Zulassungsantrag für Satralizumab (Entwicklungscode: SA237), einen humanisierten, rezyklierenden Interleukin…
L'EMA et la FDA acceptent les demandes de mise sur le marché du satralizumab de Chugai pour la maladie du spectre de la neuromyélite optique (NMOSD)
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO : 4519) a annoncé que l’Agence européenne des médicaments (EMA) a accepté la demande d’autorisation de mise sur le marché du satralizumab, (code de développement : SA237), un anticorps de r…
Glaukos Announces Participation in Stephens Investor Conference
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that …
Aldeyra Therapeutics to Host Conference Call and Webcast to Release Expanded Results from Allergen Chamber Trial and Announce Design of Phase 3 INVIGORATE Trial in Patients with Allergic Conjunctivitis
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call and webcast at 8:00 a.m. ET Thursday, October 31, 2019 to release expanded results from its allergen chamber clinical methods trial of to…
Ophthalmology Times® Announces Winners of 3rd Annual Research Scholar Honoree Program
CRANBURY, N.J.–(BUSINESS WIRE)– #AAO2019–Ophthalmology Times® Announces Winners of 3rd Annual Research Scholar Honoree Program
Aerie Pharmaceuticals to Announce Third Quarter 2019 Financial Results and Host Conference Call on Wednesday, November 6, 2019
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucom…
Aerie Pharmaceuticals Announces the Appointment of David A. Hollander, M.D., M.B.A., as Chief Research & Development Officer
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucom…
HTL investit dans des capacités de production GMP pour soutenir un marché des applications médicales de l’Acide Hyaluronique en forte croissance.
JAVENÉ, France–(BUSINESS WIRE)–HTL, leader mondial de la production d’Acide Hyaluronique et d’autres biopolymères, annonce qu’il investit dans une unité de production à la pointe de la technologie, qui multipliera par 2,5 sa capacité de production de…
HTL invests in GMP manufacturing capacity to support fast growing market of Hyaluronic Acid Medical Applications
JAVENÉ, France–(BUSINESS WIRE)– #hyaluronicacid–HTL Biotechnology invests in GMP manufacturing capacity to support the fast growing market of medical applications for Hyaluronic Acid.
Riassunto: EMA e FDA accettano le richieste di autorizzazione alla commercializzazione per satralizumab nel trattamento del disturbo dello spettro della neuromielite ottica (NMOSD)
TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) ha annunciato che l’Agenzia europea per i medicinali (European Medicines Agency, EMA) ha accettato le richieste di autorizzazione alla commercializzazione per satralizumab (codice di…
EMA and FDA Accept Marketing Applications for Chugai's Satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)
TOKYO–(BUSINESS WIRE)– #NMOSD–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application for satralizumab (development code: SA237), an anti-interleukin-6 (IL…
KARL STORZ Imaging Receives Employer/Accommodations Award
GOLETA, Calif.–(BUSINESS WIRE)–KARL STORZ Imaging received the Employer/Accommodations Award for exemplary efforts to provide career opportunities for people with disabilities.
IVERIC bio Appoints Abraham Scaria, PhD, as Chief Scientific Officer
NEW YORK–(BUSINESS WIRE)–IVERIC bio announced today the appointment of Abraham Scaria, PhD, to the position of Chief Scientific Officer, effective October 29, 2019.
Modulim Announces New CEO Richard Oberreiter
IRVINE, Calif.–(BUSINESS WIRE)– #CEO–Modulim is pleased to announce the appointment of Richard Oberreiter as its new CEO. He succeeds founder, CEO and CTO, David Cuccia.
NovaBay Pharmaceuticals to Distribute the NuLids System® for the Treatment of Dry Eye in Certain U.S. Geographies
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, announces an exclusive 90-day agreement with NuSight Medical® t…